Published Technical Disclosure Archive

Integrative Bladder Cancer Treatment Platform

Publication ID: 24-11857612_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Integrative Bladder Cancer Treatment Platform,” Published Technical Disclosure No. 24-11857612_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857612_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,612.

Summary of the Inventive Concept

A comprehensive system integrating antigen presenting cells, IL-15 based superagonists, and cutting-edge technologies like blockchain, AI, IoT, and nanomaterials to revolutionize bladder cancer treatment and patient care.

Background and Problem Solved

The original patent disclosed a vaccine composition for treating bladder cancer using antigen presenting cells and IL-15 based superagonists. However, this invention had limitations in tracking patient treatment and response, predicting treatment outcomes, and ensuring secure data storage and sharing. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful and efficient system.

Detailed Description of the Inventive Concept

The integrative platform comprises a composition including antigen presenting cells isolated from a subject treated with Bacillus Calmette-Guerin (BCG) and cultured with IL-15 based superagonists. This composition is administered to bladder cancer patients and tracked using a blockchain-based platform, which ensures secure data storage and sharing. Artificial intelligence is used to analyze patient data and predict treatment outcomes, while an IoT network enables remote monitoring and control of devices delivering the composition. Additionally, a machine learning model is trained on patient data to predict treatment outcomes, and a nanomaterial-based delivery system targets the composition to bladder cancer cells.

Novelty and Inventive Step

The new inventive concept's novelty lies in the synergistic integration of antigen presenting cells, IL-15 based superagonists, and distinct technologies like blockchain, AI, IoT, and nanomaterials. This integration provides a non-obvious solution to the limitations of the original patent, enabling a more efficient, secure, and effective treatment of bladder cancer.

Alternative Embodiments and Variations

Alternative embodiments may include using different types of immunotherapeutic primed antigen presenting cells, varying the IL-15 based superagonist complex, or incorporating other emerging technologies like quantum computing or bioprinting. Variations may also involve adapting the platform for treating other types of cancer or diseases.

Potential Commercial Applications and Market

The integrative bladder cancer treatment platform has significant commercial potential in the oncology and healthcare industries, with a target market including hospitals, research institutions, and pharmaceutical companies. The platform's ability to enhance treatment outcomes, reduce costs, and ensure secure data storage and sharing makes it an attractive solution for stakeholders in the healthcare ecosystem.

CPC Classifications

SectionClassGroup
A A61 A61K39/04
A A61 A61K35/15
A A61 A61K39/00114
A A61 A61K39/001119
A A61 A61K39/39
A A61 A61K2039/515
A A61 A61K2039/585

Field of Art

Immunotherapy and cancer treatment, specifically focusing on bladder cancer immunological interventions, with expertise in antigen presenting cell manipulation, cytokine complexes, and advanced medical technologies

Person of Ordinary Skill (PHOSITA) Profile

A biomedical researcher or immunologist with advanced training in cancer immunotherapy, familiar with cellular engineering techniques, IL-15 superagonist mechanisms, and emerging medical technology integration strategies

Obviousness Rationale

A PHOSITA would recognize that integrating blockchain, AI, IoT, and nanomaterial technologies with established BCG and IL-15 based immunotherapeutic approaches represents a predictable extension of existing cancer treatment methodologies. The technical elements disclosed in the PTD represent incremental improvements that leverage known technological platforms to enhance treatment tracking, monitoring, and delivery. These variations demonstrate standard engineering problem-solving approaches applied to an established immunotherapeutic framework.

Obvious Combinations & Variations

Source Patent Element
Antigen presenting cells isolated from BCG-treated subjects and cultured with IL-15 based superagonists
PTD Variation
Adding blockchain-based patient data tracking and AI-driven outcome prediction
Obviousness Reasoning
Integrating digital technologies for medical data management is a known technique in personalized medicine, representing a predictable application of existing technological solutions to immunotherapeutic research
Source Patent Element
IL-15:IL-15Rα fusion protein complex for immune modulation
PTD Variation
Implementing nanomaterial-based targeted delivery systems
Obviousness Reasoning
Targeted drug delivery using nanomaterials is a well-established approach in biomedical engineering, offering a finite and predictable method of improving therapeutic agent localization
Source Patent Element
Bladder cancer treatment composition using immunotherapeutic cells
PTD Variation
IoT-enabled remote monitoring of treatment devices and patient responses
Obviousness Reasoning
Remote medical device monitoring represents a standard technological enhancement in healthcare delivery, offering a logical and obvious extension of existing treatment protocols
Source Patent Element
BCG-based immunotherapeutic approach for bladder cancer
PTD Variation
Machine learning models for predicting treatment outcomes
Obviousness Reasoning
Applying predictive analytics to medical treatment data is a recognized technique in contemporary medical research, representing an obvious technological progression
Source Patent Element
Antigen presenting cell manipulation for cancer immunotherapy
PTD Variation
Integrating multiple emerging technologies like blockchain and AI into treatment platform
Obviousness Reasoning
Multidisciplinary technology integration is a standard approach in advanced medical research, representing a predictable solution to enhancing treatment efficacy and monitoring
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857612 and the disclosed Published Technical Disclosure, a person having ordinary skill in the art would find the claimed variations obvious, as they represent predictable combinations of known immunotherapeutic techniques with emerging digital technologies, thereby rendering subsequent claims of novelty non-patentable under 35 U.S.C. § 103.

Original Patent Information

Patent NumberUS 11,857,612
TitleBacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Assignee(s)NantCell, Inc.